image: The engineered 4-1BBL molecule has strong structural flexibility, allowing it to optimally engage and cluster with T cells. This material relates to a paper that appeared in the Jun. 19, 2019, issue of Science Translational Medicine, published by AAAS. The paper, by C. Claus at Roche Innovation Center Zurich in Schlieren, Switzerland; and colleagues was titled, "Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy." view more
Credit: [Credit: Dr. Philippe Ringler and Prof. Dr. Henning Stahlberg at University of Basel, Center for Cellular Imaging and NanoAnalytics (C-CINA); Dr. Matthias E. Lauer at Roche Innovation Center Basel]